The correlation of gene and protein expression changes in biological systems has been hampered by the need for separate sample handling and analysis platforms for nucleic acids and proteins. In contrast to the simple, rapid, and flexible workflow of quantitative PCR (qPCR) methods, which enable characterization of several classes of nucleic acid biomarkers (i.e. DNA, mRNA, and microRNAs), protein analysis methods such as Western blotting are cumbersome, laborious, and much less quantitative. However, TaqMan Ò Protein Assays, which use the proximity ligation assay (PLA™) technology, now expand the range of qPCR applications to include the direct detection of proteins through the amplification of a surrogate DNA template after antibody binding. Here we describe an integrated qPCR approach for measuring relative changes in gene and protein expression from the same starting sample and on a single analytical platform that pairs TaqMan Ò Gene Expression (GEx) Assays with TaqMan Ò Protein Assays. We have monitored the changes in mRNA, microRNA, and protein expression of relevant biomarkers in the pluripotent human embryonal carcinoma cell line, NTERA2, upon differentiation to neuronal cells. In addition, TaqMan Ò Protein Assays have been used to monitor protein expression in induced pluripotent stem cells (iPSC) that have been reprogrammed from human somatic cells. The data presented establishes a general paradigm utilizing real-time PCR instruments and reagents for studying the relationship between the stem cell transcriptome and proteome.
Introduction
Human embryonic stem (ES) cells can be propagated indefinitely in culture, but will differentiate into major cell lineages under specific culture conditions. NTERA2, a pluripotent human embryonal carcinoma cell line, can be induced to differentiate along neuroectodermal lineages upon exposure to retinoic acid (RA) [1] . Pluripotent cells can also be derived from somatic cells that have been reprogrammed. These induced pluripotent stem (iPS) cells have many of the same characteristics as ES cells, including the ability to differentiate into various cell lineages [2] [3] [4] . Understanding maintenance of pluripotency and commitment to cell differentiation on a molecular level is crucial to understanding developmental processes of pluripotent cells. The OCT4, NANOG, SOX2, and LIN28 proteins play critical roles in establishing or maintaining pluripotency in human ES cells. OCT4, NANOG, SOX2, and LIN28 are highly expressed in undifferentiated ES cells and can be used as markers for pluripotency [5] . mRNA transcripts often serve as the biomarker type of choice for assessing, monitoring, and/or determining the state of a cell. This is largely due to the relative ease with which such markers can be analyzed. However, it still remains to be proven that transcript profiles faithfully reflect the cellular proteome and the presence and relative abundance of their encoded proteins. TaqMan Ò Protein Assays enable an integrated qPCR approach for measuring relative changes in gene and protein expression from the same starting sample and on a single analytical platform that pairs TaqMan Ò Gene Expression Assays with TaqMan Ò Protein Assays. To validate this approach, we used NTERA2 cells as a model system and determined both mRNA and protein expression profiles and fold changes throughout the time course of induction for four stem cell pluripotency markers and two differentiation markers, NCAM1 and ALCAM. In addition, we used TaqMan Ò Protein Assays to monitor gene transfer success in somatic cells that have been transduced with several of the reprogramming genes (OCT4, SOX2, and KLF4) that are required to generate induced pluripotent stem cells (iPSC) [2] [3] [4] . TaqMan Ò Protein Assays are an adapted form of PLA™, a proximity ligation assay technology invented by Ulf Landegren, Simon Fredriksson, and colleagues, that combines antibody-protein binding with real-time PCR-based detection of the reporter nucleic acid sequence [6, 7] . The three basic steps of the assay are shown in Fig. 1 
NTERA2 sample preparation
NTERA2 cell lysates were prepared with Protein Expression Sample Prep Kit (Applied Biosystems) and assayed directly for protein. In parallel, crude cell lysates were processed for RNA with the PARIS™ kit (Applied Biosystems) and subsequently treated with TURBO DNA-free™ DNAse (Applied Biosystems). The PARIS™ mirVana kit (Applied Biosystems) was used for mircoRNA purification.
Fibroblast transduction and sample preparation
Baculovirus particles (1 Â 10 7 ) containing a polycistronic vector expressing OCT4, SOX2, KLF4, and tagRFP (Invitrogen) was transduced onto 1 Â 10 6 human dermal fibroblasts. Cells were harvested 24 h and 4 days post-transduction and cell lysates were prepared using the Protein Expression Sample Prep Kit (Applied Biosystems).
TaqMan Ò Protein Assays and reagent kits
All TaqMan Ò Protein Assays and associated reagents kits were obtained from Applied Biosystems. TaqMan Ò Protein Assays with NTERA2 cell lysates were carried out using cell lysate dilutions of 500, 125, 32, and 0 cells per reaction. TaqMan Ò Protein Assays with transduced fibroblast cell lysates were carried out using 500 and 0 cells per reaction.
TaqMan
Ò Gene Expression Assays and reagent kits mRNA assays and One-Step RT-qPCR reagents were obtained from Applied Biosystems. Gene expression Assays were performed according to the manufacturer's instructions. No reverse transcription (RT) controls verified the removal of genomic DNA after DNAse treatment. microRNA assays and Multiplex RT and qPCR reagents were obtained from Applied Biosystems. Expression changes are relative to day 0 (untreated).
fication plots using a threshold of 0.2. Protein expression fold changes between untreated and treated samples were determined by first calculating DC T s (C T for cell input minus C T for no cell input) for each lysate dilution point and for each protein target. DC T s were then plotted vs. cell input per assay reaction. The slopes from the resulting plots were used to determine fold changes. All fold changes (up and down) are relative to day 0 (untreated cells). Gene expression fold changes between untreated and treated samples were determined by first calculating DC T s (C T for each target minus C T for ACTB [mRNA], RNU48
[miRNA]) for each sample. Gene expression changes were calculated relative to day 0 using the DDC T method [8] .
Results

3.1.
Monitoring protein, mRNA and microRNA expression levels during stem cell differentiation using TaqMan based Protein Assays, Gene Expression Assays, MicroRNA Assays and qPCR TaqMan Ò Protein Assays were used to monitor protein levels during the course of RA treatment of NTERA2 cells while the mRNA and microRNA levels were monitored using TaqMan Gene Expression Assays and MicroRNA Assays, respectively. During the course of RA treatment, the stem cell protein markers NANOG, OCT4, LIN28 and SOX2 all show decreased expression in NTERA2 ( Fig. 2A) . NANOG is no longer detectable by day 4. LIN28 and OCT4 continue to be expressed, but at progressively lower levels. SOX2 protein levels decrease somewhat during the course of treatment, but recover to near normal levels by day 28. The differentiation markers NCAM1 and ALCAM both exhibit increased expression during the time course, with NCAM1 exhibiting a greater and earlier increased expression than ALCAM.
For the mRNA assays (Fig. 2B ) the relative levels of NANOG, OCT4, and LIN28 mRNA are all decreased by day 10 of the RA induction time course. Levels of NANOG and OCT4 mRNA are noticeably reduced by day 4, while SOX2 mRNA levels are somewhat reduced during the course of treatment but recover by day 28. In contrast, levels of NCAM1 and ALCAM increase throughout the induction period, with maximal expression at day 28.
Relative expression changes (DDC T s) for a panel of microRNAs (treated cells minus untreated, day 0) are shown for NTERA2 cells after 5 days of treatment (treated cells, day 5 minus untreated cells, day 0) (Fig. 3) . Negative values denote a decrease in expression, while positive values denote an increase in expression. The temporal changes in expression of specific mature microRNAs such as the Let-7 series during RA induction correlate well with temporal changes in LIN28 expression, supporting the link between LIN28 and microRNA-mediated cellular differentiation.
Monitoring protein expression after viral transduction
Human dermal fibroblasts were transduced with a vector expressing OCT4, SOX2, KLF4, and RFP (red fluorescent protein) (Fig. 4) . RFP expression can be observed 24 h post-transduction, but cannot be observed 4 days post-transduction. In contrast, OCT4, SOX2, and KLF4 protein expression was observed 24 h and 4 days post-transduction using TaqMan Ò Protein Assays.
Summary
TaqMan Ò Protein Assays were used to determine the relative expression of six target proteins in untreated and RA-treated NTERA2 cells. As expected, the levels of OCT4, NANOG, LIN28, and to a lesser extent, SOX2, declined or became undetectable in RA-induced cells as they became differentiated. In contrast, the differentiation markers NCAM1 and ALCAM were detected at much lower levels in untreated NTERA2 cells compared to RA-induced cells. TaqMan Ò Gene Expression Assays were used to determine the relative expression of the corresponding six target transcripts in untreated and RA-treated NTERA2 cells. As expected, OCT4, NA-NOG, SOX2, and LIN28 transcripts were detected at high levels in untreated cells and decreased in RA-induced cells. In contrast, transcripts for NCAM1 and ALCAM increased with RA-treatment. Overall, the protein expression profiles correlate with gene expression profiles in terms of timing and direction of changes over the course of RA induction. However, the protein and mRNA expression profiles are not identical, and the differences observed in the protein and mRNA expression profiles demonstrated here could be significant with respect to our understanding of fundamental biological processes. hsA-miR-371-hsa-miR-302d hsa-miR-367 hsa-miR-302a hsa-miR-372 hsa-miR-302b hsa-miR-376c hsa-miR-302c hsa-miR-378 hsa-let-7d Mamm U6 hsa-miR-141 hsa-miR-92a hsa-miR-200c RNU48 hsa-miR-18b hsa-miR-23b hsa-miR-18a hsa-miR-301a hsa-miR-20a hsa-miR-20b hsa-miR-19a hsa-miR-19b hsa-let-7e hsa-miR-93 hsa-miR-17 hsa-miR-106a hsa-miR-16 hsa-miR-423-hsa-miR-103 hsa-miR-218 hsa-miR-24 hsa-miR-124 hsa-miR-21 hsa-miR-221 hsa-miR-222 hsa-miR-133a hsa-let-7b hsa-miR-125b hsa-let-7c 
TaqMan
Ò Protein Assays were also used to monitor the expression of proteins in cells transduced with a vector expressing OCT4, SOX2, KLF4, and RFP. The TaqMan Ò Protein Assays proved to be more sensitive and more quantitative than fluorescence microscopy in monitoring protein expression. The TaqMan Ò Protein Assays could be used to in lieu of more cumbersome and time-consuming techniques such as immunohistochemistry or Western blotting to screen for potential iPS colonies. TaqMan Ò Protein Assays provide a simple, rapid, and sensitive method for protein relative quantification in cell lysates. Proteins can typically be detected in reactions containing 500 or less cell equivalents. Compared to typical protein detection methods such as Western blotting, the TaqMan Ò Protein Assay requires less sample, is more sensitive, and has a simpler and faster workflow. Moreover, the TaqMan Ò Protein Assay allows users to determine relative protein quantification and enables correlation to mRNA and/or miRNA expression results using the same analytical platform and provides a general paradigm for studying the relationship between the stem cell transcriptome and proteome. 
